News and Updates
Delhi High Court dismisses pleas against Centre's ban on anti-diabetic FDC medicines
New Delhi: The Delhi High Court has rejected a batch of pleas challenging the Centres notification banning manufacture and sale of fixed dose combination (FDC) drugs used for treatment of Type-II diabetes. Justice Vibhu Bakhru said there was no ground to interfere with the central governments September 7, 2018, notification and dismissed the petitions filed by eight pharma companies. The Centre had banned the FDCs of formulation of metformin, pioglitazone and gli
To continue reading this article
Continue reading your article with a Emedinexus account..